HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sophie Jacques Selected Research

Dual Specificity Phosphatase 3

12/2021Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
10/2017Dual-Specificity Phosphatase 3 Deletion Protects Female, but Not Male, Mice from Endotoxemia-Induced and Polymicrobial-Induced Septic Shock.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sophie Jacques Research Topics

Disease

1Alcoholic Fatty Liver
12/2021
1Obesity
12/2021
1Hepatocellular Carcinoma (Hepatoma)
12/2021
1Pain (Aches)
08/2018
1Septic Shock (Toxic Shock Syndrome)
10/2017
1Endotoxemia
10/2017
1Neoplasms (Cancer)
01/2017
1Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
05/2009

Drug/Important Bio-Agent (IBA)

2Dual Specificity Phosphatase 3IBA
12/2021 - 10/2017
12- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
08/2018
1Estrogens (Estrogen)FDA Link
10/2017
1EndotoxinsIBA
10/2017
1Dual-Specificity PhosphatasesIBA
01/2017
1Methylphenidate (Ritalin)FDA LinkGeneric
05/2009